Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosis
Denali to receive a milestone payment of $25 million from Sanofi for Phase 2 clinical trial initiation
Development of RIPK1 inhibitor program continues in a broad range of central nervous system and peripheral inflammatory conditions
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.